NEWS CENTER
Poseida News Center
Featured Content
Read media coverage on Poseida, find resources for the working press, and get insights from our executive leadership team on how Poseida is advancing a new class of cell and gene therapies.
Poseida in the News
Astellas taps Poseida for second CAR-T deal focused on solid tumors
|
May 1, 2024
Astellas hitches a ride in Poseida’s convertible for $50M cell therapy collaboration
|
May 1, 2024
AACR: To bring CAR-T to solid tumors, Poseida thinks we need to boost conditioning therapy
|
April 10, 2024
FDA Grants Orphan Drug Designation to P-BCMA-ALLO1 in R/R Multiple Myeloma
|
March 14, 2024
A Significant Milestone for the Future of Gene Editing
|
February 28, 2024
Poseida: New CEO, same passion for allogeneic therapies
|
February 26, 2024
Creating CAR T therapies that don’t cause cancer
|
February 16, 2024
4 Keys To Allo In 2024 With Poseida Therapeutics’ Kristin Yarema, Ph.D.
|
January 4, 2024
Executive Perspectives
Press Releases
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
|
May 1, 2024
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
|
April 18, 2024
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
|
April 17, 2024
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
|
April 17, 2024
Media Library
Usage rights & restrictions:
These media assets are free for editorial broadcast, print, online and radio use. They are restricted for other purposes.